Pramlintide

Generic Name: Pramlintide

Brand Names: Symlin

Drug Type: Small Molecule

Chemical Formula: C_₁₇₁H_₂₆₇N_₅₁O_₅₃S_₂

CAS Number: 151126-32-8

Unique Ingredient Identifier: D3FM8FA78T

Background: Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.

Indication: 用于1型和2型糖尿病的辅助治疗。

Associated Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes

Phase 2

Recruiting

Conditions: type1diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: Pramlintide
Drug: Lyumjev
Device: Automated Insulin Delivery (AID) system

First Posted Date: 2023-09-21

Last Posted Date: 2024-04-18

Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Target Recruit Count: 30

Registration Number: NCT06046417

Locations: 🇨🇦
Research Institute of the McGill University Health Center, Montreal, Quebec, Canada

A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes

Not Applicable

Completed

Conditions: Type 1 Diabetes

Interventions: Drug: Fiasp
Device: Artificial Pancreas
Drug: Pramlintide
Drug: Aspart

First Posted Date: 2022-01-20

Last Posted Date: 2023-10-25

Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Target Recruit Count: 12

Registration Number: NCT05199714

Locations: 🇨🇦
Research Institute of the McGill University Health Center, Montreal, Quebec, Canada

Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

Early Phase 1

Withdrawn

Conditions: Cutaneous Squamous Cell Carcinoma

Interventions: Drug: Pramlintide

First Posted Date: 2020-02-05

Last Posted Date: 2023-06-28

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Registration Number: NCT04252612

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

Phase 4

Completed

Conditions: Hypoglycemia
Evidence of Previous Gastric Surgery

Interventions: Drug: Pramlintide

First Posted Date: 2013-04-26

Last Posted Date: 2023-06-29

Lead Sponsor: Joslin Diabetes Center

Target Recruit Count: 22

Registration Number: NCT01841359

Locations: 🇺🇸
Joslin Diabetes Center, Boston, Massachusetts, United States

Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

Phase 4

Completed

Conditions: Type 1 Diabetes

Interventions: Drug: Insulin
Drug: Pramlintide
Drug: Exenatide

First Posted Date: 2011-01-04

Last Posted Date: 2018-04-12

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 37

Registration Number: NCT01269047

Locations: 🇺🇸
Albert Einstein College of Medicine West Campus Clinical Research Center, Bronx, New York, United States

Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus

Phase 1

Withdrawn

Conditions: Diabetes Mellitus

Interventions: Drug: Pramlintide

First Posted Date: 2010-07-20

Last Posted Date: 2018-07-26

Lead Sponsor: University of Colorado, Denver

Registration Number: NCT01165944

Locations: 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States

Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus

Phase 3

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Pramlintide

First Posted Date: 2010-06-04

Last Posted Date: 2011-10-14

Lead Sponsor: Cheryl Rosenfeld, DO

Target Recruit Count: 40

Registration Number: NCT01137695

Locations: 🇺🇸
University Physicians Group, Staten Island, New York, United States
🇺🇸
St. Mary Medical Center, Langhorne, Pennsylvania, United States
🇺🇸
North Jersey Endocrine Consultants, Denville, New Jersey, United States

Pramlintide in Adolescents With Type 1 Diabetes

Not Applicable

Completed

Conditions: Type 1 Diabetes

Interventions: Drug: pramlintide

First Posted Date: 2009-02-12

Last Posted Date: 2015-06-23

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 10

Registration Number: NCT00842075

Locations: 🇺🇸
Barbara Davis Center, Aurora, Colorado, United States

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia
Diabetes
Schizoaffective Disorder
Weight Gain

Interventions: Drug: Placebo
Drug: Pramlintide

First Posted Date: 2008-06-04

Last Posted Date: 2018-11-16

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 33

Registration Number: NCT00690235

Locations: 🇺🇸
The University of Texas Southwestern Medical Center, Dallas, Texas, United States

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

Phase 4

Withdrawn

Conditions: Type 1 Diabetes

Interventions: Drug: Pramlintide
Drug: Glargine
Drug: Aspart
Drug: Lispro

First Posted Date: 2007-07-25

Last Posted Date: 2019-01-08

Lead Sponsor: University of Texas Southwestern Medical Center

Registration Number: NCT00505882

Locations: 🇺🇸
UT Southwestern at Dallas, Dallas, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy